This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by O'Rourke, K E. Articles by Hutchinson, M Search for Related Content PubMed PubMed Citation Articles by O'Rourke, K E. Articles by Hutchinson, M Social Bookmarking                         What's this?

Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns

Department of Neurology, St. Vincent's University Hospital, Dublin, Ireland

M Hutchinson

Department of Neurology, St. Vincent's University Hospital, Dublin, Ireland, mhutchin{at}iol.ie

Estimates of the beta-interferon (IFNB) stopping rate in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) vary and have been mainly derived from multicentre studies. This is a retrospective, hospital chart-based study of 394 patients treated by a single neurologist for up to eight years. The aims of the study were to ascertain the frequency and timing of IFNß discontinuation in a well supported cohort, and to investigate whether the clinical disease type at the initiation of IFNß or the reason for discontinuation influenced stopping rates. The median follow-up was 49 months. The overall IFNß stopping rate was 28% over five years; there was a significant difference between the IFNß stopping rates for RRMS (14%) and SPMS (23%) after three years of follow-up (P=0.0003). Patients stopped IFNß due to side effects after a median of 13 months, and due to failure of therapy after a median of 35 months (P=0.0004). Significantly more patients with SPMS than with RRMS stopped IFNß due to treatment failure (P=0.037). Conclusion: IFNß discontinuation occurred earlier in the treatment course when due to side effects. Stopping IFNß therapy was more common in SPMS and was more often due to treatment failure than side effects.

Key Words: beta-interferon • multiple sclerosis • side effects • stopping • switching • treatment failure

Multiple Sclerosis, Vol. 11, No. 1, 46-50 (2005)
DOI: 10.1191/1352458505ms1131oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. M Bruce, L. M Hancock, and S. G Lynch Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report Multiple Sclerosis, January 1, 2010; 16(1): 112 - 120. [Abstract] [PDF]

				M Hutchinson Predicting and preventing the future: actively managing multiple sclerosis Practical Neurology, June 1, 2009; 9(3): 133 - 143. [Abstract] [Full Text] [PDF]

				A. P. Ross Strategies for optimal disease management, adherence, and outcomes in multiple sclerosis patients Neurology, December 9, 2008; 71(24_suppl_3): S1 - S2. [Full Text] [PDF]

				A. P. Ross Tolerability, adherence, and patient outcomes Neurology, December 9, 2008; 71(24_suppl_3): S21 - S23. [Abstract] [Full Text] [PDF]

				S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, and J Outley Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study Multiple Sclerosis, June 1, 2008; 14(5): 640 - 655. [Abstract] [PDF]

				K. O'Rourke, C. Walsh, G. Antonelli, and M. Hutchinson Predicting beta-interferon failure in relapsing-remitting multiple sclerosis Multiple Sclerosis, April 1, 2007; 13(3): 336 - 342. [Abstract] [PDF]